QOSHE - Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival - Christian Wienberg
menu_open
Columnists Actual . Favourites . Archive
We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival

10 0
13.12.2023
Novo Nordisk faces opposition from local rival, Zealand Pharma. The pharma company has so far risen 63% in market value on the Copenhagen stock exchange this year compared with 40% for its larger peer.

© Fortune


Get it on Google Play